📋 Tender Overview
Mapping The Brain-Spinal Cord Interaction Towards Understanding And Treatment Of Movement Disorders
Setting The Pace By Advancing Movement Science In Europein Our Daily Lives, Movement Is Crucial For Health. However, Over 1 Billion People Globally Face Neurological Diseases Impairing Their Mobility. Annually, 1.5 Million Eu Citizens Suffer Strokes, Demanding Innovative Solutions. In This Context, The Eic-Funded Move2Treat Pioneers A High-Performance Brain-Spinal Cord Interface To Decode Movement Generation. It Boasts Three Key Breakthroughs: A Groundbreaking Theory On Movement, A Soft-Fibre Neural Interface For Brain-Spinal Cord Communication, And Validation In Disease Models. This Heralds The ‘Next-Generation Pacemaker Of The Nervous System’, Offering Minimally Invasive, Wireless, And Biocompatible Technology To Map Brain-Spinal Cord Activity. Overall, Move2Treat Answers Europe’S Call For Technological Sovereignty, Ushering In Precision Sensing For Neurological Science.
Funded Under
The European Innovation Council (Eic)
Total Cost
€ 2 996 048,75
Eu Contribution
€ 2 996 048,75
Coordinated By
Danmarks Tekniske Universitet
Denmark
Start Date
1 July 2024
End Date
30 June 2027
Objective
Movement is one of the most important activities in our everyday life. It is an essential element for maintaining overall health and well-being, with more than 1 billion people globally suffering from a neurological disease that directly affects their movement. Each year, more than 1.5 million people experience a stroke in the EU alone leading to death, paralysis, or some kind of disability; this is a significant burden on healthcare systems with no cure. We must address the questions: How do we move? What is the underlying physical mechanism of the brain-spinal cord interaction that orchestrates the generation of movement? To be able to answer those, a high-performance bi-directional interface is required. Move2Treat explores disruptive science by developing a new brain-spinal cord interface to investigate the associated neuronal circuits. In fact, Move2Treat has 3 distinct breakthroughs: (1) a novel theory on movement generation by rotating ensembles validation the neuronal population activity across central brain regions and the spinal cord. (2) A bi-directional soft-fiber platform as neural interface to brain and spinal cord in freely behaving species. (3) Validation of theory (1) and neural interface (2) in the disease models. The developed theory and implant enable the next-generation pacemaker of the nervous system based on the first complete, minimally invasive, wireless, biocompatible and soft multifunctional fiber-based neural interface to map the brain-spinal cord activity by simultaneous stimulation/recording in vivo and real-time with high spatial and temporal resolution. Move2Treat is a European approach to establish technological sovereignty, delivering the next-generation precision sensing for neurological science
